ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder

Posted on by

ANS-858 is a new selective, reversible, orally bioavailable ALDH2 Inhibitor in pre-clinical development to reduce craving. BEL AIR, Md. and SAN FRANCISCO, May 14, 2024 /PRNewswire/ — Amygdala Neurosciences (a private company) announced today that the Company has closed a new round of…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.